Core Insights - Metagenomi's Adenine Base Editors (ABEs) demonstrate over 95% genome targetability and achieve over 95% protein knockdown in primary T-cells, indicating high efficiency and specificity in gene editing applications [1][2][3] Group 1: Targetability - The ABE platform is targetable to over 95% of the human genome's base pairs, providing a significantly wider range of sites compared to first-generation SpCas9 base editors, which enhances flexibility in addressing complex gene targets [2][3] Group 2: Efficiency - The ABE platform achieved over 95% reproducible and durable triplex protein knockdown in primary T-cells, confirming its efficiency for multiplex gene editing [3] - The platform is compatible with various non-viral methods for site-specific template integration, enabling a comprehensive editing solution for next-generation cell therapies [3] Group 3: Specificity - The ABE demonstrated highly specific on-target deamination with minimal to no indel formation, confirming no detectable translocations and no significant genomic composition differences compared to unedited cells, which minimizes the risk of unintended genetic alterations [3] Group 4: Tolerability - ABE triplex protein knockdowns exhibited excellent tolerability in cells, with no adverse effects on cell viability, expansion, or changes in stress-related gene expression observed post-editing, which is critical for maintaining cell health in therapeutic applications [4] Group 5: Company Overview - Metagenomi is a precision genetic medicines company focused on developing curative therapeutics using its proprietary metagenomics-derived toolbox, which includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems [5]
Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT